Taxotere, Docetaxel Newswire

Taxotere, Docetaxel Newswire

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic).

Results 1 - 20 of 284 in Taxotere, Docetaxel (generic)

  1. Breast cancer drugs stop working when tumors 'make their own fuel'Read the original story w/Photo

    21 hrs ago | PhysOrg Weblog

    The early-stage findings, from an international team led by Imperial College London and the European Institute of Oncology in Milan, reveal some breast tumours evolve to make their own 'fuel supply', rendering treatments powerless. The team, whose findings are published in the journal Nature Genetics , hope their work will increase treatment options for patients whose cancer has returned.

    Comment?

  2. Asia-Pacific Prostate Cancer Market Size, Growth and ForecastsRead the original story

    Thursday Jan 19 | Emailwire.com

    According to the report "Prostate Cancer Market", published by Market Data Forecast, Asia-Pacific market is projected to reach USD 14.33 billion by 2021, at a CAGR of 10.65% from 2016 to 2021. Asia-Pacific Prostate Cancer Market is projected to reach USD 14.33 billion by 2021, at a CAGR of 10.65% from 2016 to 2021.

    Comment?

  3. Cristal Therapeutics Release: Company Raises ???12.8 Million In New...Read the original story

    Wednesday Jan 18 | BioSpace

    MAASTRICHT, The Netherlands-- -- Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, today announced the closing of a 12.8 million financing round. The financing comes from a consortium headed by Dutch oncology investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures and was complemented by BOM, LIOF and LBDF.

    Comment?

  4. Cristal Therapeutics raises 12.8 million in new financing round to...Read the original story

    Thursday Jan 19 | Customer Interaction Solutions

    Cristal Therapeutics raises a 12.8 million in new financing round to advance novel medicines against cancer using its CriPec nanotech platform Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, today announced the closing of a a 12.8 million financing round. The financing comes from a consortium headed by Dutch oncology investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures and was complemented by BOM, LIOF and LBDF.

    Comment?

  5. Endocyte Inc. (ECYT) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Thursday Jan 19 | Daily Political

    According to Zacks, "Endocyte progress with its pipeline has been impressive. Currently, Endocyte is focused on the development of two candidates, EC1456 and EC1169, of which both are currently in early-stage studies.

    Comment?

  6. Endocyte, Inc. (ECYT) Downgraded by Zacks Investment Research to HoldRead the original story w/Photo

    Wednesday Jan 18 | IntersportsWire

    According to Zacks, "Endocyte progress with its pipeline has been impressive. Currently, Endocyte is focused on the development of two candidates, EC1456 and EC1169, of which both are currently in early-stage studies.

    Comment?

  7. HER2 Inhibitors Drug Class to Hold Largest Share in Global Breast...Read the original story

    Wednesday Jan 18 | PR.com

    Maryland Heights, MO, January 18, 2017 -- -- While, Aromatase Inhibitors is the fastest growing segment of the market, HER2 inhibitors segment is likely to hold the largest share of the breast cancer therapeutics market. The HER2 inhibitors are mainly used as neoadjuvant treatment of patients with HER2 positive breast cancer at early stages and for advanced metastatic breast cancer greater than 2 cm in diameter in size.

    Comment?

  8. Stock Analysts' Downgrades for January, 17thRead the original story w/Photo

    Tuesday Jan 17 | AmericanBankingNews.com

    According to Zacks, "Israel-based Cybersecurity firm, CyberArk's near-term prospects are not promising as changing customer spending behavior has recently hit several other players in this space. Intensifying competition from peers and an uncertain macroeconomic environment add to its woes.

    Comment?

  9. Research Analysts' Recent Ratings Updates for Eagle PharmaceuticalsRead the original story w/Photo

    Monday Jan 16 | AmericanBankingNews.com

    According to Zacks, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.

    Comment?

  10. Lung Cancer Therapeutics Market by Treatment Type and by Region 2021Read the original story

    Wednesday Jan 11 | Emailwire.com

    The Global Lung Cancer Therapeutics Market was worth $5.65 billion in 2016 and estimated to be growing at a CAGR of 6.7%, to reach $7.81 billion by 2021. The Lung Cancer Therapeutics Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc.

    Comment?

  11. Eagle Pharmaceuticals, Inc. (EGRX) Stock Price Down 8.6% After Insider SellingRead the original story w/Photo

    Friday Jan 6 | Daily Political

    Eagle Pharmaceuticals, Inc. 's share price dropped 8.6% on Friday following insider selling activity. The company traded as low as $75.01 and last traded at $75.17, with a volume of 579,595 shares traded.

    Comment?

  12. OncoGenex And Announce Definitive Merger AgreementRead the original story

    Thursday Jan 5 | BioSpace

    Upon completion of the proposed merger, Achieve's equity holders are expected to own 75% of the combined company's outstanding shares and current stockholders of OncoGenex are expected to own the remaining 25% of the combined company's outstanding shares. Following completion of the merger, OncoGenex Pharmaceuticals, Inc. will be renamed Achieve Life Sciences, Inc. In addition, prior to the completion of the proposed merger, OncoGenex is expected to distribute to its stockholders contingent value rights for 80% of any net proceeds of certain payments arising from a future sale, transfer, license or similar transaction involving OncoGenex's apatorsen oncology product candidate.

    Comment?

  13. New therapeutic agent proves more effective treatment for advanced prostate cancerRead the original story w/Photo

    Thursday Jan 5 | PhysOrg Weblog

    Lu-177-PSMA-617 radionuclide therapy can reduce tumor burden and induce PSA remission in patients with metastatic advanced prostate cancer. Credit: Kambiz Rahbar, M.D., Department of Nuclear Medicine, University Hospital Muenster, and Wolfgang Peter Fendler, M.D., Department of Nuclear Medicine, University Hospital Munich A German multicenter study, initiated by the German Society of Nuclear Medicine, demonstrates that lutetium-177 -labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy of patients with metastatic castration-resistant prostate cancer .

    Comment?

  14. Asia Pacific Non-Small Cell Lung Cancer Therapeutics Market Is...Read the original story w/Photo

    Wednesday Jan 4 | SBWire

    Genentech, a Roche company, dominates the global non-small cell lung cancer therapeutics market, individually accounting for more than 36% of the market shares in 2014. Transparency Market Research finds that the market is characterized by the presence of both generic and branded companies, and positions Eli Lilly and Company as the second-most prominent player.

    Comment?

  15. Easton Pharmaceuticals and Partner BMV Medica Announce Receipt of...Read the original story w/Photo

    Wednesday Jan 4 | Market Wire

    As per its recently announced distribution agreement with Gedeon Richter, Easton / BMV and their host laboratory, Ackerman Pharma, have received an initial purchase order for their in-licensed Gynofit Lactic Acid Gel Treatment with delivery from Switzerland expected later this month, and subsequent delivery to Gedeon Richter in Mexico for an expected February product launch. This agreement coincides with its recent distribution agreement executed with Windsor Pharmaceuticals for Central America which is pending regulatory approval.

    Comment?

  16. Biosimilar Trastuzumab Shows Promise in Phase 3 TrialRead the original story

    Wednesday Dec 28 | P&T Community

    Phase 3 results have confirmed the efficacy, safety, and immunogenicity of MYL-1401O , a proposed biosimilar trastuzumab, in comparison with that of branded trastuzumab . Branded trastuzumab is indicated for the treatment of patients with certain human epidermal growth factor receptor 2 -positive breast and gastric cancers.

    Comment?

  17. Global Lung Cancer Therapeutics Market is projected to reach USD 7.81 ...Read the original story

    Dec 24, 2016 | Emailwire.com

    Global Lung Cancer Therapeutics Market is projected to reach USD 7.81 Billion by 2021, at a CAGR of 6.7% from 2016 to 2021. Research report by marketdataforecast.com with in-depth analysis on Lung Cancer Therapeutics Market which provides information on market size, share, forecasts and company profiles for major industry participants 2016-2021 According to the report Lung Cancer Therapeutics Market , published by Market Data Forecast, the global market is projected to reach USD 7.81 Billion by 2021, at a CAGR of 6.7% from 2016 to 2021.

    Comment?

  18. Global Prostate Cancer Market Research Analysis Report 2016 to 2021Read the original story

    Dec 21, 2016 | Emailwire.com

    Prostate Cancer Market by Diagnostic Techniques and Prostate Specific Antigen Test ), by Surgery ), by Radiation Therapy According to the report Prostate Cancer Market , published by Market Data Forecast, the global market is projected to reach USD 75.56 Billion by 2021, at a CAGR of 9.5% from 2016 to 2021. View Report at Prostate cancer is cancer which occurs in a man's prostate.

    Comment?

  19. Merck & Co. Release: KEYTRUDA (Pembrolizumab) Approved As First...Read the original story

    Dec 18, 2016 | BioSpace

    Merck , known as MSD outside the United States and Canada, today announced that KEYTRUDAA , the company's anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients with PD-L1-positive unresectable advanced/recurrent non-small cell lung cancer in the first- and second-line treatment settings at a fixed dose of 200 mg every three weeks. MSD will manufacture and market KEYTRUDA in Japan and will promote it with Taiho Pharmaceutical Co., Ltd. This approval in both the first- and second-line settings for advanced non-small cell lung cancer in patients whose tumors express PD-L1 marks an important milestone in Japan," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories.

    Comment?

  20. BeyondSpring Pharmaceuticals Presents Encouraging Clinical Data For...Read the original story

    Dec 18, 2016 | BioSpace

    Plinabulin offers same-day dosing versus next-day dosing for G-CSF, by which time a significant insult to Neutrophils has occurred. Plinabulin also reduced the clinical sequelae associated with Docetaxel-induced Neutropenia .

    Comment?